Background: There is only limited information about cost-effectiveness of drug-eluting stents compared with bare metal stents in Turkey. Aims: The purpose of this study was to evaluate the bare-metal stents and drug-eluting stents used in the treatment of coronary artery disease from the perspective of the reimbursement institution with costeffectiveness analysis. Study Desing: Retrospective Cost Effectiveness Analysis Method: In our study 329 patients were investigated, who were diagnosed with coronary artery disease and treated with bare-metal stent or drug-eluting stent in the cardiology clinics of a public university hospital between January 1 and December 31, 2016. Bare-metal stents and drug-eluting stents used in the treatment of coronary artery disease were evaluated retrospectively with cost-effectiveness analysis from the perspective of the reimbursement institution. Results: The cost of treatment with bare metal stent was 2,131.41 Turkish Liras (TL) and the cost of treatment with drug-eluting stent was 3,546.14 TL; the QALY value of the treatment with bare metal stent was 0.8371 and the QALY value of the treatment with drug-eluting stent was 0.8924 and all these data were analyzed by decision tree. As a result of decision tree analysis, the weighted cost of treatment with bare metal stent was 2,340.71 TL and weighted QALY value was 0.8332; and the weighted cost of treatment with drug-eluting stent was 3,970.90 TL and the weighted QALY value of the treatment with drug-eluting stent was 0.8911. With these values, the additional cost-effectiveness ratio was calculated as 28,179.12 TL per acquired QALY. The additional costeffectiveness ratio is in the 1st zone in the cost-effectiveness plane and below the very cost-effectiveness threshold. Conclusion: In our study, it was concluded that drug-eluting stents are cost-effective compared to bare metal stents in the treatment of coronary artery disease. Considering the cost and effectiveness of the drug-eluting stent, it is thought that making more reimbursement for this technology by the reimbursement agency would be beneficial for the service provider.
allocation of health services in a society, has attempted to provide a solution to this problem through health technology assessment (HTA). With HTA studies the distinctive alternatives of delivering a health service can be compared in terms of cost and effectiveness. In the Global Burden of Disease Study (4) , cardiovascular disease is the worldwide leading cause of mortality among the first five diseases leading to the highest loss of life in 2016 (5) . In National Burden of Disease studies carried out in Turkey, cardiovascular diseases were seen to take the first place among the 25 DALY causes in 2013 as well as in 2000 (6) . Coronary artery disease (CAD) is one of the important causes of cardiovascular mortality worldwide (1, (7) (8) (9) . Considering the resources used for diagnosis and treatment of this disease, which has been becoming widespread in developed and developing countries (9) , it is observed that the cost of this disease has a high share in health systems. In order to reduce the recurrent revascularization process in CAD treatment, drug-eluting stent (DES) has been developed as an alternative to a bare-metal stent (BMS). The use of DES in the treatment of CAD shows more effective results in terms of restenosis and recurrent revascularization, than BMS (10, 11) . Due to the fact that the cost of the DES is more than the BMS, some restrictions and arrangements have been made now and then by the Social Security Institution (SSI), with regard to reimbursement. In order to use DES in CAD treatment, the conditions specified in National Communiqué on Healthcare Implementation must be met. With the latest amendment made in the National Communiqué on Healthcare Implementation and published in the Official Gazette No. 30175, dated 09/09/2017 (12), the material repayment amount for KR1151 coded DES was reduced from 1,018.00 TL to 650.00 TL. Our study was carried out with the aim of comparing the BMS and DES which is used in CAD treatment with the cost effectiveness analysis from SSI perspective, which is the reimbursement institution, evaluating the burden of the disease on the national budget in case of treatment with these technologies and calculating the effects of related technologies on quality of life. Our study is thought to be original in this respect. Method In our study, BMSs and DESs which are used in the treatment of coronary artery disease were evaluated retrospectively with cost effectiveness analysis from SSI perspective. The study population was composed of 329 people with the diagnosis of coronary artery disease in cardiology clinics of a university hospitals between January 1 -December 31, 2016, and BMS was used in 102 patients and DES was used in 227 patients. The sampling procedure was not done in the study and the whole universe was included in the study. In the scope of the study, telephone calls were made to implement the EQ 5D 5L Health Survey. Some people in the study universe could not be reached due to incorrect or incomplete contact information. As a result of telephone calls, 130 patients (68.42%) in whom DES had been used, and 60 patients (31.58%) in whom BMS were used for the treatment were reached. Ethical approval for the study (date:19.04.2017, number: 85434274-050.04.04/27789) were obtained from the Ankara University Ethics Committee. Patient billing data obtained from hospital data management system were classified under headings of anesthesia, surgery, framework agreement services, pharmacy, cardiology, blood bank, laboratory, radiology, medical equipment, bedding and other expenses and total expenditure by means of Microsoft Excel 2016 program.. The total of expenditures made for the two comparison groups were calculated separately. The share of these expenditure items in the total costs and the average expenditure per capita from each one of these items were determined. The average cost per patient was calculated for both of these health technologies. In the study, Ouality Adjusted Life Years (QALY) was used as a measure of effectiveness. In this context, QALY calculations were made for BMS and DES by conducting the "EuroQol (EQ) 5D 5L Health Ouestionnaire" to the patients in the study by telephone calls. The EQ 5D 5L Health Questionnaire consists of five dimensions: mobility, self-care, normal work, pain/discomfort and anxiety/status of low spirit. These five dimensions contain 5-point likert responses. A 5-digit score is obtained when the responder gives a score for all dimensions. This score is assessed by country-specific weights on a standard scale, where measurement of "0" indicates death and "1" indicates excellent health. Quality of life weights of EQ 5D 5L Health Questionnaire for Turkey is not available. Therefore, the evaluation was made with the weights of the countries which are frequently used in the cost effectiveness studies and most resembling to Turkey's health structure. Germany's quality of life weights were used for QALY calculation and, Dutch quality of life weights were used for sensitivity analysis. In addition, for the comparison of efficacy, hospital admissions and mean hospitalization days were analyzed for the same health problem in the last 1 year after the treatment period of the patients. The costs, effectiveness, possible results and realization possibilities of BMS and DES were determined and two different decision trees based on cost and QALY values were formed. The decision tree was drawn with the Precision Tree 7.5 extension of the Microsoft Excel Program and the weighted cost and effectiveness values were obtained to be used in calculating the additional cost-effectiveness ratio. The weighted cost was calculated by multiplying the costs of the DES and BMS used in CAD treatment by the probability of occurrence. The weighted QALY values were calculated by multiplying the QALY values of DES and BMS by the probability of occurrence. After calculating the Incremental Cost Effectiveness Ratio (ICER), this ratio was assessed by the threshold value to determine whether alternative technology was included within acceptable limits for cost u n c o r r e c t e d p r o o f effectiveness. Gross Domestic Product per Capita was taken as a threshold value indicator according to World Health Organization recommendation (13) . The threshold value calculated by the effective sales rate (moving average) of the Central Bank in 2016 was evaluated as the threshold of the very cost effectiveness and the threshold of the 3 times of the value effectiveness. In our study, due to the use of one-year data, no reduction process was performed. One Way Sensitivity Analysis was implemented to measure the sensitivity of the study results to possible uncertainties. In the case of the use of BMS or DES in the treatment of coronary artery disease, a budget effect analysis was conducted to determine the burden on the national budget. The incidence figures of CAD in Turkey, and Onat and colleagues' work (2015) was used for the analysis of the budget effect. The effects on the country budget is calculated if patients are treated with these technologies.
Results
In the scope of the study, 60 people (31.58%) with DES treatment and 130 people (68.42%) with BMS treatment have been reached. 31.67% of the patients with BMS treatment were female and 68.33% were male; and 30% of the patients with DES treatment were female and 70% were male When the age distribution is examined; 50% of the BMS group was under 65 years old, 50% was 65 years and over; 56.15% of the DES group were under 65 years of age and 43.85% were 65 years of age and over. When the treatment units are examined; 81.67% of the BMS group was hospitalized in the clinic and 18.33% was in intensive care unit; however 100% of the DES group were inpatients in the clinic. It was seen that 58.33% of the patients in the BMS group had concomitant diseases and 41.67% did not have concomitant diseases. In the DES group, 62% of the patients had concomitant diseases, while 38%'inin did not have concomitant diseases (Table 1) . Looking at the cost findings in Table 2 ; BMS technology has a total cost of 127,884.51 TL and an average cost of 2,131.41 TL per patient. It is determined that the expense item occupying the largest share in total cost is medical equipment with a ratio of 49.44%. This is followed respectively by surgery with 12.66%, cardiology with 11.63%, pharmacy with 7.47%, hospital bed costs with 6.14%, laboratory investigations with 5.40%, framework agreement services with 4.34%, blood bank with 0.68%, anesthesia with 0.39%, radiologic investigations with 0.23% and miscellaneous costs with 1,62% (pain treatment applications, nephrology, physical therapy, outpatient clinic). As for DES technology, it has a total cost of 460,997.75 TL and an average cost of 3,546.14 TL per patient. It is determined that the expense item with the largest share in total costs in this group was also medical supplies with a ratio of 70.25%. This is followed respectively by surgery with 12.29%, drug costs with 4.69%, framework agreement services with 3.75%, cardiology services with 3.19%, laboratory investigations with 2.76%, hospital bed costs with 2.15%, blood bank with 0.2%, anesthesia with 0.06%, radiologic investigations with 0.02% and miscellenaous costs with 0.51%. Table 3 shows the effectiveness findings of the study. The QALY value of treatment with BMS was calculated as 0.8371 and the QALY value of treatment with DES was calculated as 0.8924. Within the scope of the Visual Analog Scale (VAS), which is the second part of the EQ 5D 5L Health Questionnaire, patients were asked to give their current health a score on the scale in which zero point express the worst health level imaginable and hundred points express the best health level imaginable. According to the responses of the patients, the mean VAS value of the patients who used BMS in their treatment was 64.03 and the mean VAS value of the patients with DES was 72.56. When the hospital visits with the same health problem in the last one year after the treatment period were investigated; It was observed that 35.2% of BMS users and 19.23% of those who use DES were re-admitted. The mean duration of hospitalization of the BMS group was 1.93 days while the mean hospitalization duration of hospitalization of the DES group was 1.59 days. Figure 1 shows the cost decision tree. Accordingly, the weighted cost value of BMS technology is 2,340.71 TL and the weighted value of DES technology is 3,970.90 TL. As a requirement of cost effectiveness analysis, the low-cost alternative was chosen and the model determined the BMS as the decision. Figure 2 shows the effectiveness decision tree. Accordingly, it is seen that the BMS weighted QALY value is 0.8332 and the DES weighted QALY value is 0.8911. As a requirement of cost effectiveness analysis, the alternative with high efficiency was chosen; the model determined the DES as the decision. In order to determine the necessary additional cost to obtain additional QALY with DES technology compared to BMS technology, ICER was calculated by weighted cost and effectiveness values obtained by decision tree. It is observed that DES requires an incremental cost of 1,630.19 TL compared to BMS. When the effectivenss of the two technologies were compared, it was found that the QALY value of DES was 0.0579 units more than the QALY value of BMS. ICER for treatment with DES versus BMS technology for the management of coronary artery disease is 28,179.12 TL per acquired QALY. This means that treatment with DES technology requires an incremental cost of 28,179.12 TL to achieve additional QALY ( Figure 3 , ICER ranks in the 1st zone and below the very cost-effectiveness threshold. This situation implies that DES is more costly and more effective than BMS. Based on the position taken by ICER in the cost-effectiveness plane, DES was found to be very cost-effective compared to BMS. One-Way Sensitivity Analysis was performed to measure the sensitivity of the results of cost-effectiveness analysis to unpredictable uncertainties. In this context, the cost and effectiveness findings of the study were changed. When the cost of treatment with DES is increased by 10%, the additional cost is 2.025.72 TL and the ICER is 35.016,26 TL per QALY. When this is increased by 20%, the additional cost is 2.421.27 TL and the ICER is 41.853.58 TL per QALY. When Dutch quality of life weights are used instead of Germany, the additional effectiveness ratio is calculated as 0,1169 and ICER is calculated as 13,940,31 TL per QALY earned. As a result, ICER was found to vary between 13,940,31 TL and 41,853,58 TL. When the cost of DES was increased by 10% in the One-Way Sensitivity Analysis, and the QALY was calculated using Dutch weights, ICER remained very cost-effective. With a 20% increase in DES cost, ICER approached towards the costeffectiveness threshold from the very cost-effectiveness threshold. The budget effect analysis was performed as a complement to the cost effectiveness assessment of the DES and BMS used in CAD treatment, and the burden of CAD on the country budget was calculated when CAD was treated with these health technologies. The incidence of coronary artery disease in Turkey is 2.5% (14). Turkey's population is described by TÜİK as 79,814,871 people, as of December 31, 2016. To estimate the number of patients with coronary heart disease, the incidence of coronary artery disease is proportioned to Turkey's population and it is calculated to be 1,995,372 people. Table 5 presents the results of the budget impact analysis from the SSI perspective, in order to evaluate the burden on the country's budget in case of the use of BMSs and medicated stents in the treatment of coronary artery disease. It is seen that CAD has a share of 3.90% in total health expenditures in case of treatment with BMS and having a share of 6.62% of total health expenditures if treated with DES. Discussion In our study, it was aimed to compare the cost and effectiveness of BMSs and DESs used in treatment of CAD, to determine whether DES is cost effective compared to BMS and to determine the burden of using these health technologies in the treatment, on the country budget. When the costs of these two health technologies are compared, it is concluded that DES is more costly than BMS. With the survey of the related literature, it is found that the cost of DES is more than the cost of BMS too in studies with similar or different perspectives, as in our study (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . When the literature is examined, it is seen that DESs decrease recurrent revascularization compared to BMSs [16, 29] and show more positive results. In our study, several parameters were used to compare efficacy and it was concluded that DES was more effective than BMS. The QALY value of patients treated with DES (0.8924) was found to be higher than the QALY value of patients treated with BMS (0.8371). The VAS score of the DES group (72.56) was higher than the VAS score (64.03) of the BMS group. Treatment with DES in terms of rehospitalization (19.23%) is more advantageous than BMS (35%). The mean length of hospital stay (1.59 days) of patients treated with DES was shorter than the mean length of hospital stay (1.93 days) of patients treated with BMS. In studies on this subject, efficacy was compared with various parameters and the efficiency of DES was found to be higher than the efficiency of BMS (19, 23, 24, 26, 27) . Some studies in the literature also concluded that DES is more effective in high-risk patients (17, 18, 20, 22) . ICER, calculated with weighted values obtained from the decision tree analysis of cost and effectiveness data, was found to be 28,179.12 TL per additional QALY. From this point of view, DES was found to be very cost effective compared to BMS. In their study, Cohen et al. found DES to be cost effective compared to BMS (2004) . In some studies either, DES was found to be cost-effective in high-risk patients (17, 18, 20, 21) . However in Kutluer's study, DES was not found to be cost effective according to BMS (2015) . In this study, it is thought that this result is achieved because the QALY values which are the criterion of effectiveness are taken the same for DES and BMS. 
Study limitations
The results of the study should be evaluated within the framework of some limitations. The most important of these are; due to the inavailability of the weights of the quality of life for Turkey in the EQ 5D 5L Health Questionnaire, using the life quality weights of Germany; because the study is retrospective each other patient having different duration elapsed after the procedure; lack of contact information for some patients, or missing or incorrect information; the inability to reach the entire study universe due to the fact that some people do not live any longer. Patients who did not respond to all EQ 5D 5L Health Questionnaire questions were not included in the study. To be able to make an accurate cost-effectiveness comparison between two health technologies, patients in whom both BMS and DES were used at the same time were not included in the study. In this study, it is determined that DESs are more costly than BMSs but they are more advantageous in terms of effectiveness. In the cost-effectiveness analysis, it was concluded that DES was very cost-effective compared to u n c o r r e c t e d p r o o f BMS. In case of CAD treatment with BMS, the budget effect is 4,728,891,929.42 TL and the budget effect is 8,022,260,039.81 TL if treated with DES. From this point of view, it is seen that treatment with DES has a higher budget effect. Considering that human health is more important than book value, using DES in CAD treatment is predicted to create more patient satisfaction. With the amendment made in the National Communiqué on Healthcare Implementation and published in the Official Gazette No. 30175, dated 09/09/2017 (12), the reimbursement for DES was reduced from 1,018.00 TL to 650.00 TL. Considering the effectiveness of DES, it is thought that it would be beneficial for service providers to pay more for this technology. It is recommended that policymakers develop policies to prevent coronary artery disease, which has a large budget impact.
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